GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Joinn Laboratories (China) Co Ltd (HKSE:06127) » Definitions » Cash Conversion Cycle

Joinn Laboratories (China) Co (HKSE:06127) Cash Conversion Cycle : 703.42 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Joinn Laboratories (China) Co Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Joinn Laboratories (China) Co's Days Sales Outstanding for the three months ended in Mar. 2025 was 57.05.
Joinn Laboratories (China) Co's Days Inventory for the three months ended in Mar. 2025 was 667.4.
Joinn Laboratories (China) Co's Days Payable for the three months ended in Mar. 2025 was 21.03.
Therefore, Joinn Laboratories (China) Co's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2025 was 703.42.


Joinn Laboratories (China) Co Cash Conversion Cycle Historical Data

The historical data trend for Joinn Laboratories (China) Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Joinn Laboratories (China) Co Cash Conversion Cycle Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 207.72 253.75 454.37 557.46 451.43

Joinn Laboratories (China) Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 784.84 429.83 416.98 320.90 703.42

Competitive Comparison of Joinn Laboratories (China) Co's Cash Conversion Cycle

For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Joinn Laboratories (China) Co's Cash Conversion Cycle Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Joinn Laboratories (China) Co's Cash Conversion Cycle falls into.


;
;

Joinn Laboratories (China) Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Joinn Laboratories (China) Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2024 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=35.46+427.92-11.95
=451.43

Joinn Laboratories (China) Co's Cash Conversion Cycle for the quarter that ended in Mar. 2025 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=57.05+667.4-21.03
=703.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Joinn Laboratories (China) Co  (HKSE:06127) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Joinn Laboratories (China) Co Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Joinn Laboratories (China) Co's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Joinn Laboratories (China) Co Business Description

Traded in Other Exchanges
Address
A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a non-clinical contract research organization(CRO) focused on drug safety assessment. It operates in three segments: Non-clinical studies services include drug safety assessment, drug metabolism & pharmacokinetics (DMPK) studies, & pharmacology & efficacy studies; Clinical trial & related services segment provides early-stage services such as clinical CRO services, co-managed phase I clinical research units, & bioanalytical services, and: Sales of research models engages in the design, production, breeding, & sales of research models, currently including non-human primates and rodents. The majority is from the Non- Clinical studies services. Its geographical segments are China, the United States, and Other countries, of which the majority is from China.
Executives
Yi Fang Da Ji Jin Guan Li You Xian Gong Si 2102 Investment manager
Futu Trustee Limited 2301 Trustee
Ubs Group Ag 2201 Interest of corporation controlled by you
Aggregate Of Abrdn Plc Affiliated Investment Management Entities 2102 Investment manager
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co. 2502 Approved lending agent
Fidelity Funds 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Abrdn Asia Focus Plc 2101 Beneficial owner
Morgan Stanley 2201 Interest of corporation controlled by you
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Apg Asset Management N.v. 2101 Beneficial owner
Apg Groep N.v. 2101 Beneficial owner

Joinn Laboratories (China) Co Headlines

No Headlines